Ligands of Immunopharmacology

N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.In VitroBMS-202 inhibits PD-1/PD-Ll interaction, and may augment therapeutic immune response to a number

N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.In VitroBMS-202 inhibits PD-1/PD-Ll interaction, and may augment therapeutic immune response to a number

N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.In VitroBMS-202 inhibits PD-1/PD-Ll interaction, and may augment therapeutic immune response to a number

N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.In VitroBMS-202 inhibits PD-1/PD-Ll interaction, and may augment therapeutic immune response to a number

Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC 50 s of 8.72 and 5.15 μM, respectively in cell

Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC 50 s of 8.72 and 5.15 μM, respectively in cell

Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC 50 s of 8.72 and 5.15 μM, respectively in cell

Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC 50 s of 8.72 and 5.15 μM, respectively in cell

Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC 50 s of 8.72 and 5.15 μM, respectively in cell

Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC 50 s of 8.72 and 5.15 μM, respectively in cell

Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza , inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathwaysIn VitroNeocryptotanshinone exhibits anti-inflammatory effect by suppression of

Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza , inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathwaysIn VitroNeocryptotanshinone exhibits anti-inflammatory effect by suppression of